• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    12/8/21 4:56:37 PM ET
    $ADTX
    $APTX
    $AQST
    $BJDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADTX alert in real time by email

    Gainers

    • Aptinyx (NASDAQ:APTX) shares rose 4.72% to $2.66 during Wednesday's after-market session. Trading volume for this security closed at 80.2K, accounting for 49.36% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $180.1 million.
    • iSpecimen (NASDAQ:ISPC) shares rose 4.24% to $14.75. The market value of their outstanding shares is at $128.5 million.
    • Reshape Lifesciences (NASDAQ:RSLS) stock rose 3.96% to $2.1. The company's market cap stands at $7.3 million.
    • Bluejay Diagnostics (NASDAQ:BJDX) stock rose 3.86% to $2.69. The market value of their outstanding shares is at $34.1 million.
    • Odonate Therapeutics (NASDAQ:ODT) stock rose 3.86% to $1.88. The market value of their outstanding shares is at $72.3 million.
    • Aquestive Therapeutics (NASDAQ:AQST) stock rose 3.66% to $5.65. Today's trading volume for this security ended up closing at 129.0K shares, which is 24.55 percent of its average volume over the last 100 days. The company's market cap stands at $226.9 million.

    Losers

    • Phreesia (NYSE:PHR) shares fell 5.3% to $51.0 during Wednesday's after-market session. Phreesia's trading volume hit 59.0K shares by close, accounting for 15.66% of its average volume over the last 100 days. The company's market cap stands at $2.5 billion. The company's, Q3 earnings came out today.
    • BioSig Technologies (NASDAQ:BSGM) stock declined by 4.73% to $2.62. The market value of their outstanding shares is at $92.5 million.
    • Ensysce Biosciences (NASDAQ:ENSC) shares fell 4.7% to $2.84. This security traded at a volume of 150.6K shares come close, making up 4.82% of its average volume over the last 100 days. The company's market cap stands at $68.8 million.
    • Aditxt (NASDAQ:ADTX) stock fell 2.72% to $0.81. The market value of their outstanding shares is at $35.2 million.
    • PetVivo Holdings (NASDAQ:PETV) stock fell 2.28% to $4.3. The company's market cap stands at $41.8 million.
    • Jaguar Health (NASDAQ:JAGX) stock declined by 2.25% to $1.3. The market value of their outstanding shares is at $59.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADTX
    $APTX
    $AQST
    $BJDX

    CompanyDatePrice TargetRatingAnalyst
    Phreesia Inc.
    $PHR
    4/1/2026Mkt Outperform → Mkt Perform
    Citizens
    Phreesia Inc.
    $PHR
    3/31/2026$10.00Outperform → Neutral
    Robert W. Baird
    Phreesia Inc.
    $PHR
    3/31/2026$11.00Buy → Hold
    Truist
    Phreesia Inc.
    $PHR
    3/31/2026$10.00Buy → Neutral
    Citigroup
    Phreesia Inc.
    $PHR
    3/31/2026$16.00Overweight → Neutral
    Analyst
    Phreesia Inc.
    $PHR
    3/31/2026$35.00 → $14.00Buy
    Needham
    Phreesia Inc.
    $PHR
    1/9/2026$30.00Overweight
    Wells Fargo
    Phreesia Inc.
    $PHR
    1/9/2026$26.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $ADTX
    $APTX
    $AQST
    $BJDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Pale Fire Capital Se

    4 - Phreesia, Inc. (0001412408) (Issuer)

    4/2/26 6:45:03 PM ET
    $PHR
    Real Estate

    SEC Form 4 filed by Gandhi Balaji

    4 - Phreesia, Inc. (0001412408) (Issuer)

    3/27/26 5:21:15 PM ET
    $PHR
    Real Estate

    SEC Form 4 filed by Hoffman Allison C

    4 - Phreesia, Inc. (0001412408) (Issuer)

    3/25/26 5:00:22 PM ET
    $PHR
    Real Estate

    $ADTX
    $APTX
    $AQST
    $BJDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Phreesia Announces Fourth Quarter Fiscal 2026 Results

    Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal fourth quarter and fiscal year ended January 31, 2026. "We achieved several critical financial milestones ahead of our internal targets, including achieving positive GAAP net income ($2.3 million) and crossing $100 million of Adjusted EBITDA1 and $50 million of free cash flow2 ($78.8 million net cash from operating activities) for fiscal year 2026," said CEO and Co-Founder Chaim Indig. Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q4 Fiscal 2026 Stakeholder Letter. Fiscal Fourth Quarter Ended January 31, 2026 Highlights Total reven

    3/30/26 4:03:00 PM ET
    $PHR
    Real Estate

    Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

    Reaffirms guidance to resubmit the Anaphylm NDA in Q3 2026Received clarifying feedback from the FDA on pharmacokinetic (PK) and human factor (HF) study designsFinal FDA meeting minutes expected by early May 2026 WARREN, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the receipt of preliminary comments and successful completion of an in-person Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the resubmission of the Company's New Drug

    3/30/26 7:00:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phreesia Named One of Becker's Top Places to Work in Healthcare

    Phreesia, a leader in patient intake, outreach and activation, has been named one of Becker's Healthcare's Top Places to Work in Healthcare for 2026. This marks Phreesia's second time being included on the list, which recognizes hospitals, health systems and healthcare companies that invest in their people through strong benefits, professional development and workplace practices that support engagement and retention. "We're proud to be recognized by Becker's as a top place to work in healthcare," said Amy VanDuyn, Phreesia's SVP of Human Resources. "As a fully remote company, we stay focused on connection, growth and support so our teams can do meaningful work tied to our mission to make

    3/24/26 4:09:00 PM ET
    $PHR
    Real Estate

    $ADTX
    $APTX
    $AQST
    $BJDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for LIBERVANT issued to AQUESTIVE THERAPEUTICS INC

    Submission status for AQUESTIVE THERAPEUTICS INC's drug LIBERVANT (ORIG-1) with active ingredient DIAZEPAM has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218623, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

    4/29/24 7:48:13 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $APTX
    $AQST
    $BJDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Phreesia downgraded by Citizens

    Citizens downgraded Phreesia from Mkt Outperform to Mkt Perform

    4/1/26 8:19:23 AM ET
    $PHR
    Real Estate

    Phreesia downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Phreesia from Outperform to Neutral and set a new price target of $10.00

    3/31/26 8:08:36 AM ET
    $PHR
    Real Estate

    Phreesia downgraded by Truist with a new price target

    Truist downgraded Phreesia from Buy to Hold and set a new price target of $11.00

    3/31/26 8:07:55 AM ET
    $PHR
    Real Estate

    $ADTX
    $APTX
    $AQST
    $BJDX
    SEC Filings

    View All

    SEC Form DEF 14A filed by Aditxt Inc.

    DEF 14A - Aditxt, Inc. (0001726711) (Filer)

    4/3/26 4:37:32 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Ensysce Biosciences Inc.

    8-K - Ensysce Biosciences, Inc. (0001716947) (Filer)

    4/3/26 4:14:43 PM ET
    $ENSC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phreesia Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Phreesia, Inc. (0001412408) (Filer)

    4/3/26 4:02:51 PM ET
    $PHR
    Real Estate

    $ADTX
    $APTX
    $AQST
    $BJDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner A.L. Sarroff Fund, Llc bought 1,250,000 shares (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    3/13/26 5:10:25 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Large owner A.L. Sarroff Fund, Llc converted options into 974,809 shares and bought $77,999 worth of shares (154,840 units at $0.50) (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    1/16/26 4:38:39 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Large owner A.L. Sarroff Fund, Llc bought $485,355 worth of shares (718,358 units at $0.68) and converted options into 4,033,209 shares (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    1/16/26 4:38:14 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    $ADTX
    $APTX
    $AQST
    $BJDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PetVivo Holdings Inc.

    SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)

    11/19/24 3:38:53 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Ensysce Biosciences Inc.

    SC 13G - Ensysce Biosciences, Inc. (0001716947) (Subject)

    11/14/24 5:52:56 PM ET
    $ENSC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Bluejay Diagnostics Inc.

    SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

    11/14/24 5:49:49 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    $ADTX
    $APTX
    $AQST
    $BJDX
    Leadership Updates

    Live Leadership Updates

    View All

    Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer

    Thomas A. Zalewski, a Partner at Day Pitney LLP, appointed Chief Legal Officer and Chief Compliance Officer effective April 2, 2026Lori J. Braender to remain in a non-executive role as Corporate Secretary after nearly eight years as Chief Legal Officer, Chief Compliance Officer and Corporate Secretary WARREN, N.J., March 20, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer, effective Apr

    3/20/26 7:00:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phreesia and Sesame Workshop Win Point of Care Excellence Award for Best Unbranded Campaign

    Phreesia, a leader in patient intake, outreach and activation, and Sesame Workshop, the global nonprofit behind Sesame Street, received the Point of Care Excellence Award for their pediatric health and wellness campaign. The award, announced at the Point of Care Marketing Association's (POCMA) POC Now Summit on March 18, recognizes outstanding campaigns, strategies, and individuals advancing patient and HCP engagement through innovative point-of-care (POC) marketing. The two organizations announced a five-year collaboration in August 2025, and in October launched a six-part campaign to engage millions of parents and caregivers with educational and entertaining messages to help keep thei

    3/19/26 9:03:00 PM ET
    $PHR
    Real Estate

    Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer

    Busch brings public company leadership and capital markets experience to support Ignite's next phase of growth Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"). Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein profiling. The platform measures active proteins inside tumors to help oncologists determine which targeted therapies are most

    3/19/26 8:15:00 AM ET
    $ADTX
    $GMRE
    $XRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    $ADTX
    $APTX
    $AQST
    $BJDX
    Financials

    Live finance-specific insights

    View All

    Phreesia Announces Fourth Quarter Fiscal 2026 Results

    Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal fourth quarter and fiscal year ended January 31, 2026. "We achieved several critical financial milestones ahead of our internal targets, including achieving positive GAAP net income ($2.3 million) and crossing $100 million of Adjusted EBITDA1 and $50 million of free cash flow2 ($78.8 million net cash from operating activities) for fiscal year 2026," said CEO and Co-Founder Chaim Indig. Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q4 Fiscal 2026 Stakeholder Letter. Fiscal Fourth Quarter Ended January 31, 2026 Highlights Total reven

    3/30/26 4:03:00 PM ET
    $PHR
    Real Estate

    Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

    Ignite plans to launch a new program in 2026 supporting treatment selection for more than 600,000 people in the United States living with metastatic cancer and limited therapeutic options. Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the acquisition of Ignite Proteomics, LLC ("Ignite"), a commercial-stage precision oncology company focused on addressing a critical challenge in cancer care: optimizing therapy selection. Ignite's functional proteomics platform has demonstrated the ability to identify cancer therapy responses that may not be captured by standard genomic testing alone. Aditxt

    3/13/26 8:15:00 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026; Type A meeting with FDA expected to occur within 30 daysOn track to submit regulatory applications for Anaphylm in Canada and the EU in 2026Extends revenue sharing agreement with RTW to June 30, 2027Excluding one-time items, meets 2025 guidance for revenue and non-GAAP adjusted EBITDA lossGuides to end FY2026 with cash and cash equivalents of $70 millionCompany to host investment community conference call on March 5, 2026 WARREN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring m

    3/4/26 4:01:00 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care